Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27021686 | 0.79 | NLRP3 (0.48) | NLRP3 | |
| SCHEMBL9230550 | 0.78 | L3MBTL1 (0.47) | TSHRL3MBTL1HSD11B1 | |
| SCHEMBL3548718 | 0.77 | CA1 (0.52) | DHFRTSHRSMN1; SMN2TDP1HTT | |
| SCHEMBL9231458 | 0.77 | L3MBTL1 (0.46) | SMN1; SMN2L3MBTL1HSD11B1KDM4E | |
| SCHEMBL23887319 | 0.75 | DHFR (0.53) | DHFRTSHRSMN1; SMN2TDP1KDM4E | |
| SCHEMBL19630968 | 0.75 | POLB (0.56) | TSHRL3MBTL1 | |
| SCHEMBL30754385 | 0.75 | POLB (0.56) | TSHRL3MBTL1 | |
| SCHEMBL28282283 | 0.75 | KAT6A (0.53) | DHFRTSHRSMN1; SMN2TDP1KDM4E | |
| SCHEMBL30307520 | 0.75 | DHFR (0.53) | DHFRTSHRSMN1; SMN2TDP1KDM4E | |
| SCHEMBL14328457 | 0.75 | NSD2 (0.47) | SMN1; SMN2L3MBTL1HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | HAVCR2, FURIN, SARS1 | DHFR 418/4885TSHR 4543/4885SMN1; SMN2 676/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | DHFR 4332/4885TSHR 370/4885SMN1; SMN2 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.